Photodynamic Therapy With Verteporfin for Corneal Neovascularization

This study has been completed.
Sponsor:
Information provided by:
Chonnam National University Hospital
ClinicalTrials.gov Identifier:
NCT00471406
First received: May 8, 2007
Last updated: October 16, 2008
Last verified: October 2008
  Purpose

Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization.

Design: Prospective, non-comparative case series. Participants: Eighteen eyes of 18 patients with stable corneal neovascularization who were refractory to conventional treatment.

Methods: The patients were treated with photodynamic therapy with verteporfin (6 mg/m2). Five patients were treated following penetrating keratoplasty, and 2 patients were treated before penetrating keratoplasty. Best corrected visual acuity and anterior segment photography were performed before and after treatment. The length of cumulative blood vessels and area of corneal neovascularization were measured.

Main outcome measures: Vascular occlusion, best corrected visual acuity, cumulative blood vessel length, and corneal neovascularization area.


Condition Intervention
Corneal Neovascularization
Procedure: Photodynamic Therapy with Verteporfin

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Chonnam National University Hospital:

  Eligibility

Ages Eligible for Study:   35 Years to 70 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patients with clinically stable corneal neovascularization who were not improved after treatment with 1% prednisolone acetate eyedrops instilled 4 times a day for at least 1 month

Exclusion Criteria:

  • Individuals who had active keratitis with vessel proliferation, uncontrolled inflammation, active hepatitis or clinically significant liver disease, or porphyria or other porphyrin sensitivity
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00471406

Sponsors and Collaborators
Chonnam National University Hospital
Investigators
Study Director: Kyung chul Yoon, MD Chonnam natianl university hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00471406     History of Changes
Other Study ID Numbers: CPDT-0001
Study First Received: May 8, 2007
Last Updated: October 16, 2008
Health Authority: Korea: Food and Drug Administration

Additional relevant MeSH terms:
Neovascularization, Pathologic
Corneal Neovascularization
Metaplasia
Pathologic Processes
Corneal Diseases
Eye Diseases
Verteporfin
Photosensitizing Agents
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 17, 2014